

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

ChemoMetec: NC-250 Automated Cell Analyzer

RRID:SCR_025290

Type: Tool

Proper Citation

ChemoMetec: NC-250 Automated Cell Analyzer (RRID:SCR_025290)

Resource Information

URL: <https://chemometec.com/nucleocounters/nc-250/>

Proper Citation: ChemoMetec: NC-250 Automated Cell Analyzer (RRID:SCR_025290)

Description: Automated cell analyzer, which can characterize cell properties using fluorescence imaging. Offers optimized protocols to meet needs of all mammalian cell types grown under different conditions. Cell count can be performed even on cells growing on microcarriers and in sphere cultures. Performs high-speed cell count and viability determination and offers unique 5-minute Cell Cycle Assay and 1-minute Apoptosis Assay for up to eight samples at the time. The intuitive software has unlimited licenses and produces on-screen data analysis and automated PDF reports., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Synonyms: NucleoCounter NC-250 Automated Cell Analyzer, NucleoCounter NC-250, ChemoMetec NucleoCounter NC-250

Resource Type: instrument resource

Keywords: ChemoMetec, benchtop image cytometer, cell analyzer, cell counter,

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: ChemoMetec: NC-250 Automated Cell Analyzer

Resource ID: SCR_025290

Alternate IDs: Model_Number_NucleoCounter_NC-250

Record Creation Time: 20240427T053230+0000

Record Last Update: 20260808T190714+0000

Ratings and Alerts

No rating or validation information has been found for ChemoMetec: NC-250 Automated Cell Analyzer.

No alerts have been found for ChemoMetec: NC-250 Automated Cell Analyzer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sherif S, et al. (2026) A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. Cancers, 18(9).